Your browser doesn't support javascript.
loading
Ethnicity and insurance status predict metastatic disease presentation in prostate, breast, and non-small cell lung cancer.
Aghdam, Nima; McGunigal, Mary; Wang, Haijun; Repka, Michael C; Mete, Mihriye; Fernandez, Stephen; Dash, Chiranjeev; Al-Refaie, Waddah B; Unger, Keith R.
Afiliación
  • Aghdam N; Department of Radiation Medicine, MedStar-Georgetown Hospital, Washington, DC, USA.
  • McGunigal M; Department of Radiation Medicine, MedStar-Georgetown Hospital, Washington, DC, USA.
  • Wang H; MedStar Health Research Institute, Hyattsville, MD, USA.
  • Repka MC; NYU Winthrop Hospital, New York, NY, USA.
  • Mete M; MedStar Health Research Institute, Hyattsville, MD, USA.
  • Fernandez S; MedStar Health Research Institute, Hyattsville, MD, USA.
  • Dash C; Georgetown Lombardi Comprehensive Cancer Center, Office of Minority Health & Health Disparities Research, Washington, DC, USA.
  • Al-Refaie WB; MedStar-Georgetown Surgical Outcomes Research Center, Washington, DC, USA.
  • Unger KR; MedStar-Georgetown University Hospital, Washington, DC, USA.
Cancer Med ; 9(15): 5362-5380, 2020 08.
Article en En | MEDLINE | ID: mdl-32511873
ABSTRACT

BACKGROUND:

Ethnicity and insurance status have been shown to impact odds of presenting with metastatic cancer, however, the interaction of these two predictors is not well understood. We evaluate the difference in odds of presenting with metastatic disease in minorities compared to white patients despite access to the same insurance across three common cancer types.

METHODS:

Using the National Cancer Database, a multilevel logistic regression model that estimated the odds of metastatic disease was fit, adjusting for covariates including year of diagnosis, ethnicity, insurance, income, and region. We included adults diagnosed with metastatic prostate, non-small cell lung cancer (NSCLC), and breast cancer from 2004 to 2015.

RESULTS:

The study cohort consisted of 1 191 241 prostate cancer (PCa), 1 310 986 breast cancer (BCa), and 1 183 029 NSCLC patients. Private insurance was the most protective factor against metastatic presentation. Odds of presenting with metastatic disease were 0.190 [95% CI, 0.182-0.198], 0.616 [95% CI, 0.602-0.630], and 0.270 [95% CI, 0.260-0.279] for PCa, NSCLC, and BCa compared to uninsured patients, respectively. Private insurance provided the most significant benefit to non-Hispanic White PCa patients with 81% reduction in odds of metastatic presentation and conferred the least benefit to African-American NSCLC patients at 30.4% reduction in odds of metastatic presentation.

CONCLUSIONS:

Insurance status provided the single most protective effect against metastatic presentation. This benefit varied for minorities despite similar insurance. Reducing metastatic disease presentation rates requires addressing social barriers to care independent of insurance.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Neoplasias de la Mama / Carcinoma de Pulmón de Células no Pequeñas / Cobertura del Seguro / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude Límite: Female / Humans / Male Idioma: En Revista: Cancer Med Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata / Neoplasias de la Mama / Carcinoma de Pulmón de Células no Pequeñas / Cobertura del Seguro / Neoplasias Pulmonares Tipo de estudio: Prognostic_studies / Risk_factors_studies Aspecto: Determinantes_sociais_saude Límite: Female / Humans / Male Idioma: En Revista: Cancer Med Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos